Physician profile
Marcos Reyes
NPI 1942485842
$2,983.31
in general payments reported to CMS, 2019-2025
18 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $388 · 2021: $412 · 2022: $254 · 2023: $1,318 · 2024: $82.75 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881 · Travel and Lodging: $683 · Honoraria: $71.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.48 |
| Travel and Lodging | $682.56 |
| Honoraria | $71.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,875.60 | 2019-2025 | Clareon, Argos, Centurion |
| Allergan, INC. | $211.22 | 2020-2021 | |
| New World Medical,INC. | $204.06 | 2023-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Johnson & Johnson Surgical Vision, INC. | $139.17 | 2019-2023 | Tecnis Simplicity |
| Rxsight INC | $82.19 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $69.55 | 2020-2021 | |
| Abbott Laboratories | $55.03 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $53.18 | 2023 | Acthar |
| Abbvie INC. | $45.41 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $38.91 | 2020-2021 | |
| Beaver-Visitec International, INC. | $36.16 | 2019 | |
| Biotissue Holdings INC. | $35.17 | 2025 | |
| Sight Sciences, INC. | $34.05 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $30.68 | 2022-2023 | Vyzulta |
| Aerie Pharmaceuticals, INC. | $23.91 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $18.79 | 2025 | |
| Kala Pharmaceuticals, INC. | $15.25 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.